Stops along the RAS pathway in human genetic disease

@article{BentiresAlj2006StopsAT,
  title={Stops along the RAS pathway in human genetic disease},
  author={Mohamed Bentires-Alj and Maria I. Kontaridis and Benjamin G. Neel},
  journal={Nature Medicine},
  year={2006},
  volume={12},
  pages={283-285}
}
Mutations in components of the RAS-MAPK pathway provide a unifying mechanism for several phenotypically overlapping, yet clinically distinct human 'neuro-cardio-facial-cutaneous' (NCFC) syndromes. These rare diseases may provide new insights into the regulation of this pathway and its role in various cancers. 
History of Noonan Syndrome and Related Disorders
Deregulation of the RAS pathway by some recently discovered germline mutations reveals that this pathway, known to play an impohrtant role in human oncogenesis, also plays an important role in fetal d
Sending out an SOS
TLDR
Two papers now identify gain-of-function mutations in the Ras nucleotide exchange factor SOS1 as a new player in this common developmental disorder Noonan syndrome.
Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway
TLDR
The aim of the present study was to conduct a comprehensive genetic analysis of RAS/RAF/MEK/ERK pathway in these syndromes, including Noonan syndrome, Costello syndrome and cardio‐facio‐cutaneous syndrome.
Hyperactive Ras in developmental disorders and cancer
TLDR
The implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis are discussed.
Hyperactive Ras in developmental disorders and cancer
TLDR
The implications of germline mutations in the Ras–Raf–MEK–ERK pathway for understanding normal developmental processes and cancer pathogenesis are discussed.
Clinical and molecular aspects of RAS related disorders
TLDR
Findings in germline mutations in genes coding for components of the RAS signalling cascade point to important roles for this evolutionary conserved pathway not only in oncogenesis, but also in cognition, growth and development.
Genetics of Noonan syndrome – a new gene, and the search is still on
TLDR
Germline gain‐of‐function mutations in SOS1 cause Noonan syndrome, according to a new study published in Nature Genetics.
DLC1: a significant GAP in the cancer genome.
TLDR
In vivo evidence that DLC1, a negative regulator of Rho, is a tumor suppressor gene deleted almost as frequently as p53 in common cancers such as breast, colon, and lung is provided.
NF1 Gene Structure and NF1 Genotype/Phenotype Correlations
TLDR
This inherited disorder is due to germline mutations of the NF1 gene and affects many cell types and involves multiple body systems.
...
...

References

SHOWING 1-10 OF 16 REFERENCES
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome
TLDR
Dysregulation of the RAS-RAF-ERK pathway is a common molecular basis for the three related disorders of Cardio-facio-cutaneous syndrome, which phenotypically overlaps with Noonan and Costello syndrome.
Germline mutations in HRAS proto-oncogene cause Costello syndrome
TLDR
Four heterozygous de novo mutations of HRAS are identified in 12 of 13 affected individuals, suggesting that germline mutations in HRAS perturb human development and increase susceptibility to tumors.
Dysregulation of the TSC-mTOR pathway in human disease
TLDR
Emerging evidence for a functional relationship between the mTOR signaling pathway and several genetic diseases is discussed, and evidence supporting a model in which dysregulation of mTOR may be a common molecular basis for hamartoma syndromes and for other cellular hypertrophic disorders is presented.
Targeting the mitogen-activated protein kinase cascade to treat cancer
The RAS–mitogen activated protein kinase (MAPK) signalling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth and
Diverse Biochemical Properties of Shp2 Mutants
TLDR
It is proposed that activated mutants of Shp2 modulate signaling from specific stimuli to a subset of effectors and provide a theoretical framework for understanding the complex relationship between Shp1 activation, intracellular signaling, and pathology.
Noonan syndrome and related disorders: genetics and pathogenesis.
TLDR
A mouse model of PTPN11-related Noonan syndrome was recently generated, providing a reagent for studying disease pathogenesis in greater depth as well as experimenting with novel therapeutic strategies.
Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation
TLDR
It is shown that a single Ptpn11 gain-of-function mutation evokes all major features of Noonan syndrome by acting on multiple developmental lineages in a gene dosage–dependent and pathway-selective manner.
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects*
TLDR
The results establish that the pathogenesis of LS and NS is distinct and suggest that these disorders should be distinguished by mutational analysis rather than clinical presentation.
Germline KRAS mutations cause Noonan syndrome
TLDR
These studies establish germline KRAS mutations as a cause of human disease and infer that the constellation of developmental abnormalities seen in Noonan syndrome spectrum is, in large part, due to hyperactive Ras.
...
...